ArticleFrontiers in veterinary science2025
Pharmacometrics modeling and simulation to assist phenobarbital dose optimization in dogs.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Phenobarbital (PB) remains the first-line treatment for canine epilepsy due to its efficacy, affordability, and favorable pharmacokinetics. However, its narrow therapeutic index and substantial interindividual variability necessitate therapeutic drug monitoring (TDM) and individualized dosing. This study aimed to develop and validate a population pharmacokinetic (popPK) model of PB in dogs to support model-informed precision dosing (MIPD) in clinical practice. Methods: A total of 121 serum samples from 100 dogs receiving PB monotherapy at steady state were used to build the model. An external dataset comprising 53 samples from 50 dogs was used for validation. Modeling was performed using nonlinear mixed-effects (NLME) techniques in MonolixSuite 2023R1. Covariate analysis included age, sex, and body weight (WT). Model performance was assessed using goodness-of-fit plots, prediction-corrected visual predictive checks (pcVPC), and calculation of mean error (ME), mean relative error (MRE), and root mean square error (RMSE). Monte Carlo simulations were conducted to evaluate the probability of target attainment (PTA) under different dosing regimens. Results: A one-compartment model with autoinductive clearance (CL) best described PB pharmacokinetics. WT and age were significant covariates on apparent clearance (CL/F). The model accurately predicted PB concentrations in the external dataset (ME = -0.08 mg/L, MRE = 0.04%, RMSE = 2.04%). Simulations identified optimal dosing regimens stratified by age and WT, including recommendations for loading doses to accelerate attainment of therapeutic concentrations. Discussion: The validated popPK model enables individualized PB dosing in dogs, accounting for variability in WT and age. This approach supports the implementation of MIPD in veterinary practice and may improve therapeutic outcomes while minimizing toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.